| 1 |
Elranatamab
💬 | 1件: Elranatamab Elranatamab (B-CELL MATURATION ANTIGEN ANTI-BCMA/ANTI-CD3 BISPECIFIC MAB) | 1件: Elranatamab Elranatamab | 1件: CD3E CD3E 💬
| 11件: Chagas disease Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬 | 1件: 28 28 💬
|
| 2 |
Linvoseltamab
💬 | 1件: Linvoseltamab Linvoseltamab (human IgG4-based anti-CD3 x anti-BCMA bispecific monoclonal antibody that binds to CD3 and BCMA) | 1件: Linvoseltamab Linvoseltamab | 1件: TNFRSF17 TNFRSF17 💬
| 2件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production 💬 | 1件: 28 28 💬
|
| 3 |
Mezagitamab
💬 | 1件: Mezagitamab Mezagitamab (Anti-Cd38 monoclonal antibody TAK-079) | 1件: Mezagitamab Mezagitamab | 1件: CD38 CD38 💬
| 6件: Calcium signaling pathway Calcium signaling pathway, Hematopoietic cell lineage, Nicotinate and nicotinamide metabolism, Oxytocin signaling pathway, Pancreatic secretion, Salivary secretion 💬 | 2件: 63 63, 66 💬
|
| 4 |
Muromonab-CD3
💬 | 1件: Muromonab Muromonab (Anti-CD3) | 1件: ANTI-CD3 ANTI-CD3 | 3件: CD3D CD3D,
CD3E,
CD3G 💬
| 11件: Chagas disease Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬 | 1件: 96 96 💬
|
